Approved Partner Program
TissueInsight® is a flexible diagnostic service. It can be accessed either directly from a customer LIMS, or through approved digital pathology solution providers.
Flagship Biosciences is committed to working with digital pathology solution providers with open standards, solution interoperability and strong customer focus. If you would like to utilize TissueInsight within the framework of an overall digital pathology workflow solution, we recommend the following trusted partners.
Gestalt Diagnostics
Gestalt Diagnostics® has developed PathFlow™, an enterprise software platform specifically designed to bring the benefits of digital workflow to pathologists and pathology laboratories. This product was originally developed, by what is now Gestalt’s team, to support a fully digital reading platform for radiology. The radiology platform is used in leading hospitals across the United States and supports more than 15 million studies annually. Gestalt has expanded and redesigned this proven, robust solution to work in the laboratory space – engineered for the unique needs and workflow of pathologists. Improving the Speed and Accuracy of Disease Diagnosis and Treatment Outcomes. Because days matter.
Inspirata
Inspirata®, Inc. helps patients fighting cancer, and the clinicians they trust, make every moment matter. Our comprehensive cancer informatics solutions bring together disparate data throughout the entire cancer care journey to drive informed decisions that improve survivorship.
We’ve assembled the most advanced and proven technologies to help you address the complex challenges of delivering cancer care and conducting ground-breaking research. We combine leading digital pathology solutions with automated cancer registry solutions, comprehensive cancer informatics and advanced patient engagement tools to bring you the broadest oncology informatics platform available globally.
Paige
Paige was founded in 2017 by Thomas Fuchs, Dr.Sc., David Klimstra, M.D., and colleagues from Memorial Sloan Kettering Cancer Center (MSK). The company builds computational pathology products designed so patients and their care teams can make effective, more informed treatment decisions. With this new class of AI-based technologies positioned to drive the future of diagnostics, Paige created a platform to deliver this novel technology to pathologists to transform their workflow and increase diagnostic confidence and productivity. Paige’s products deliver insights to pathologists and oncologists so they can arrive efficiently at more precise diagnoses for patients. Paige is the first company to receive FDA approval for an AI-based digital pathology product.
